192189-16-5Relevant articles and documents
New Enzyme Inhibitor Compounds
-
Paragraph 0183; 0184, (2013/05/08)
Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.
NEW ENZYME INHIBITOR COMPOUNDS
-
Page/Page column 35, (2011/10/10)
Compounds of formula (I) are inhibitors of Semicarbazide-sensitive amine oxidase wherein R1, A, X and R2 are as defined in the claims.
5-AZAINDOLE BISPHOSPHONATES
-
Page/Page column 28, (2010/04/25)
Novel 5-azaindole bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.
Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl- dipyridodiazepinones
Kelly,McNeil,Rose,David,Shih,Grob
, p. 2430 - 2433 (2007/10/03)
Modification of the non-nucleoside inhibitor of HIV-1 reverse transcriptase nevirapine (Viramune) by incorporation of a 2-indolyl substituent confers activity against several mutant forms of the enzyme.